Abstracts Archive - Page 2049 of 2607 - ACR Meeting Abstracts

Abstract Number: 2785 • 2014 ACR/ARHP Annual Meeting
Joint Specific Positional Differences in Coding and Noncoding Transcriptome of Synovial Fibroblasts As a Determinant of the Susceptibility of Synovial Joints to Rheumatoid Arthritis
Caroline Ospelt¹, Maria Armaka², Giancarlo Russo³, Anna Bratus³, Michelle Trenkmann⁴, Emmanuel Karouzakis¹, Christoph Kolling⁵, Renate E. Gay⁴, George Kollias⁶, Steffen Gay¹ and Mojca Frank Bertoncelj¹, ¹Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Institute of Immunology,, Biomedical Sciences Research Center 'Alexander Fleming', Vari, Greece, ³Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ⁵Schulthess Clinic, Zurich, Switzerland, ⁶Institute of Immunology, Biomedical Sciences Research Center 'Alexander Fleming', Vari, Greece
Background/Purpose The molecular mechanisms underlying the topographic differences in the susceptibility of synovial joints to develop rheumatoid arthritis (RA) are unknown. Positional embryonic expression of…
Abstract Number: 2786 • 2014 ACR/ARHP Annual Meeting
Aortitis: Outcomes from a Cohort of 196 Patients
Alison Clifford¹, Amr Arafat², Jahanzaib Idrees², Eric Roselli², Carmela D. Tan³, E. Rene Rodriguez³, Lars Svensson², Eugene Blackstone² and Gary S. Hoffman¹, ¹Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ²Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, ³Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Idiopathic aortitis is a rare diagnosis that may occur in the context of a primary systemic vasculitis, as part of a systemic autoimmune disease,…
Abstract Number: 2787 • 2014 ACR/ARHP Annual Meeting
Identification of Urinary Biomarkers for Lupus Nephritis
Carolina Landolt-Marticorena¹, Stephenie Prokopec², Heather Reich³, James Scholey⁴, Carmen Avila-Casado⁵, Paul R. Fortin⁶, Paul Boutros² and Joan Wither⁷, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²Ontario Institute for Cancer Research, Toronto, ON, Canada, ³Nephrology, University Health Network, Toronto, ON, Canada, ⁴Department of Medicine, The Toronto Western Hospital, Toronto, ON, Canada, ⁵Pathology, University Health Network, Toronto, ON, Canada, ⁶Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, ⁷Immunology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) is a major determinant of morbidity and mortality in Systemic Lupus Erythematosus (SLE). Variability in clinical course, underlying renal injury, and…
Abstract Number: 2788 • 2014 ACR/ARHP Annual Meeting
Preliminary Population- Based Incidence and Prevalence Estimates of SLE: The California Lupus Surveillance Project
Maria Dall'era¹, Kurt Snipes², Miriam Cisternas³, C. Gordon⁴ and Charles G. Helmick⁵, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²California Department of Public Health, Sacramento, CA, ³MGC Data Services, San Diego, CA, ⁴Rheumatology (East Wing), Medical School, Birmingham, United Kingdom, ⁵National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Previous estimates of prevalence and incidence of systemic lupus erythematosus (SLE) in the United States have varied widely. The California Lupus Surveillance Project (CLSP)…
Abstract Number: 2789 • 2014 ACR/ARHP Annual Meeting
Medical Marijuana Related Outcomes in Patients with Systemic Lupus Erythematosis
Basmah Jalil¹, Wilmer Sibbitt Jr.², Romy Cabacangun³, Clifford Qualls⁴, Arthur Bankhurst⁵ and Roderick Fields⁶, ¹Internal Medicine/Rheumatology, University of New Mexico, Albuquerque, NM, ²Internal Medicine/Rheumatology, University of New Mexico HSC, Albuquerque, NM, ³Rheumatology, UNM, Albuquerque, NM, ⁴Biostatistics, UNM, Albuquerque, NM, ⁵Rheum/ MSC 105550, University of NM Med Ctr, Albuquerque, NM, ⁶Internal Medicine/ Rheumatology, University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose Medical cannabis is used extensively in the United States, usually in the form of smoked marijuana. There is growing research regarding the immunomodulatory effects…
Abstract Number: 2790 • 2014 ACR/ARHP Annual Meeting
CMR with Quantitative T2 Mapping in Patients with Active SLE
Stacy P. Ardoin¹, Wael N. Jarjour², Subha V. Raman², Amanda Kibler² and Tam Tran², ¹Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ²Ohio State University, Columbus, OH
Background/Purpose: Cardiovascular (CV) disease is an important cause of morbidity in systemic lupus erythematosus (SLE) . Myocarditis is considered an uncommon complication of SLE…
Abstract Number: 2791 • 2014 ACR/ARHP Annual Meeting
Lung Cancer in SLE
Sasha Bernatsky¹, Rosalind Ramsey-Goldman², Michelle Petri³, Murray B. Urowitz⁴, Dafna D. Gladman⁴, Edward H. Yelin⁵, Christine Peschken⁶, John G. Hanly⁷, James E. Hansen⁸, Jean-Francois Boivin⁹, Lawrence Joseph¹⁰, Patrice Chrétien Raymer¹¹, Mruganka Kale¹², Ann E. Clarke¹³ and Systemic Lupus International Collaborating Clinics (SLICC)¹⁴, ¹Clinical Epidemiology - Rheumatology, McGill University, Montreal, QC, Canada, ²FSM-300, Northwestern University, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁶Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁷Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ⁸Therapeutic Radiology, Yale University, New Haven, CT, ⁹Department of Epidemiology & Biostatistics, McGill University, Montreal, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ¹²Clinical Epidemiology Rheum, RI McGill Univ Health Ctr, Montreal, QC, Canada, ¹³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁴Systemic Lupus International Collaborating Clinics (SLICC), ON, Canada
Background/Purpose: Lung cancer is 50% more common in SLE patients than their sex and age-matched counterparts. Our objective was to assess lung cancer risk in…
Abstract Number: 2792 • 2014 ACR/ARHP Annual Meeting
Methotrexate Prevents Inflammatory Osteolysis By Activation of the Adenosine a_2A Receptor (A2AR)
Aranzazu Mediero¹, Tuere Wilder² and Bruce N. Cronstein³, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Medicine, division of Translational Medicine, NYU School of Medicine, New York, NY, ³NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Prior studies demonstrate that adenosine, acting at A2AR, mediates the anti-inflammatory effects of methotrexate (MTX) in models of both acute and chronic inflammation. We…
Abstract Number: 2793 • 2014 ACR/ARHP Annual Meeting
BMP2 Requires TGF-Beta to Induce Osteophytes during Experimental Osteoarthritis
Esmeralda Blaney Davidson¹, Arjen Blom², Arjan van Caam¹, Elly Vitters², Miranda Bennink¹, Wim van den Berg², Fons van de Loo³ and Peter van der Kraan⁴, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁴Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Osteophytes are a major hallmark of osteoarthritis (OA). Both TGF-beta and BMP2 can induce osteophytes in murine knee joints. We demonstrated that TGF-beta could…
Abstract Number: 2754 • 2014 ACR/ARHP Annual Meeting
Predictors of Quality of Life in Behçet’s Syndrome
Selma Bozcan¹, Yesim Ozguler¹, Koray Tascilar¹, Caner Saygin¹, Didem Uzunaslan¹ and Gulen Hatemi², ¹University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: Quality of life is commonly impaired in patients with chronic inflammatory diseases. The disease itself as well as the drugs used may be responsible…
Abstract Number: 2755 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Quality of Life in BEHÇET’S Disease: The Role of Patients Reportedoutcomes
Elena Elefante¹, Rosaria Talarico², Chiara Stagnaro³, Anna d'Ascanio⁴, Antonio Tavoni⁵, Chiari Tani¹, Chiara Baldini¹, Marta Mosca⁶ and Stefano Bombardieri², ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Rheumatology Unit, Pisa, Italy, ³Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Internal Medicine, University of Pisa, Pisa, Italy, ⁵University of Pisa, Immunoallergology Unit, Pisa, Italy, ⁶V. Roma 67, 56126 Pisa, S. Chiara, Pisa, Italy
Background/Purpose Behçet’s disease (BD) is a systemic vasculitis, typically characterised by recurrent oro-genital ulcers, ocular inflammation and skin manifestations; articular, vascular, gastro-enteric and neurological involvement…
Abstract Number: 2756 • 2014 ACR/ARHP Annual Meeting
Treatment of Mucocutaneous Manifestations in Behçet’s Disease with Anakinra: A Pilot Open-Label Study
Peter C. Grayson¹, Yusuf Yazici², Elaine Novakovich³, Elizabeth Joyal⁴, Raphaela T. Goldbach-Mansky⁴ and Cailin H. Sibley^3,5, ¹NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³National Institutes of Health Clinical Center, Bethesda, MD, ⁴NIAMS, National Institutes of Health Clinical Center, Bethesda, MD, ⁵Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: IL-1 blocking therapy shows promise in the treatment of Behçet’s eye disease, but its effect on mucocutaneous manifestations is unknown. Methods: 6 patients with…
Abstract Number: 2757 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients
Hélène Vallet¹, Sophie Rivière², Alban Deroux³, Guillaume Moulis⁴, Olga Addimanda⁵, Carlo Salvarani⁶, Marc Lambert⁷, Philip Bielfeld⁸, Pascal Sève⁹, Jean Sibilia¹⁰, Jean Baptiste Fraison¹¹, Yoland Schoindre¹², Isabelle Marie¹³, Laurent Perard¹⁴, Thomas Papo¹⁵, Damien Sène¹⁶, Gaelle Leroux¹⁷, Valerie Royant¹⁸, Antoinette Perlat¹⁹, Xavier Mariette²⁰, Olivier Lidove²¹, Olivier Fain²², Claire De Moreuil²³, Gilles Blaison²⁴, Phuc LE Hoang²⁵, Eric Hachulla²⁶, Bertrand Wechsler²⁷, Barham Bodaghi²⁸, Patrice Cacoub²⁹ and David Saadoun³⁰, ¹Internal medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Internal Medicine, Lapeyronie, Montpellier, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Internal Medicine department, Toulouse, Toulouse, France, ⁵S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, ⁶Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁷CHRU Lille, Lille, France, ⁸CHU de Dijon, Dijon, France, ⁹Internal medicine, CHU Lyon, Lyon, France, ¹⁰Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹¹Hôpital Jean Verdier, Bondy, France, ¹²DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, PARIS, France, ¹³CHU de Rouen, Rouen, France, ¹⁴Hospices civils de Lyon, Lyon, France, ¹⁵Hôpital Bichat, Paris, France, ¹⁶Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁷Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ¹⁸Chartres, Chartres, France, ¹⁹Internal medicine, CHU de Rennes, Rennes, France, ²⁰rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ²¹Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, ²²Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, ²³CHU, Brest, France, ²⁴Internal medicine, CHR, Colmar, France, ²⁵Ophtalmology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpétrière, Paris, France, ²⁶Internal Medicine, National Scleroderma Centre, Lille CEDEX, France, ²⁷Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²⁸Ophtalmology, Hôpital de la Pitié Salpêtrière, Paris, France, ²⁹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ³⁰DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France
Background/Purpose Behçet’s disease (BD) is a systemic large vessel vasculitis with recurrent genital and oral ulceration, uveitis, cardiovascular, joints, neurological or gut symptoms. Treatment of…
Abstract Number: 2758 • 2014 ACR/ARHP Annual Meeting
Predictive Factors for the Response to Infliximab Therapy in Patients with Behçet’s Disease
Salvatore D'Angelo¹, Pietro Leccese¹, Angela Padula¹, Angelo Nigro¹, Michele Gilio², Antonio Carriero¹, Carlo Palazzi¹ and Ignazio Olivieri¹, ¹Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy, ²San Carlo Hospital, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy
Background/Purpose: To identify the clinical factors predicting a good clinical response to Infliximab (IFX) therapy after 12 months in patients with Behçet’s disease (BD) refractory…
Abstract Number: 2759 • 2014 ACR/ARHP Annual Meeting
Anti-TNF Treatment for Refractory Vascular Involvement of Behçet’s Syndrome
Vedat Hamuryudan¹, Emire Seyahi¹, Melike Melikoglu², Serdal Ugurlu¹, Gulen Hatemi¹, Sebahattin Yurdakul¹ and Hasan Yazici², ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: The optimal management of major vascular involvement in patients with Behçet’s syndrome (BS) is still a challenge. Methods: We reviewed the charts of 16…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].